Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07209326 · 1 trial · 2 indications
blood pressure, pulse rate, temperature, respiration rate
| Arm | Type | Description |
|---|---|---|
| Treatment Healthy Participants | EXPERIMENTAL | Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326 |
| Placebo Healthy Participants | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Treatment for SCD | EXPERIMENTAL | Participants will receive a multiple dose of subcutaneous PF-07209326 |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | Participants will receive matching placebo |
| PF-07209326 | BIOLOGICAL | Participants will receive SC or IV single ascending doses |
Inclusion Criteria Health Participants: 1\. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria Healthy Participants: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, immunocomprom...
PF-07209326 is an investigational monoclonal antibody being developed by Pfizer, Inc. (PFE) for use in hematology. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants and in participants with sickle cell disease, though it is not yet approved for any indication.
PF-07209326 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for potential use in hematology, specifically in the context of sickle cell disease, based on a completed Phase 1 trial.
PF-07209326 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in healthy participants and participants with sickle cell disease.
PF-07209326 is in Phase 1 clinical development. It has completed a Phase 1 dose escalation study in healthy participants and participants with sickle cell disease. The drug is investigational and has not been approved by regulatory authorities for any use.
PF-07209326 has been studied in one completed clinical trial, NCT04255875, titled "Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease." This Phase 1 trial enrolled 52 participants in the United States and was placebo-controlled and double-blind.
No alternative names for PF-07209326 have been disclosed. The drug is known by its development code PF-07209326 and is being studied by Pfizer for potential use in hematology, including sickle cell disease.